News tagged with her2
Researchers use light to measure cancer cells' response to treatment
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon ...
Dec 20, 2011 |
5 / 5 (1) |
0
Turning off cancer's growth signals
One hallmark of cancer cells is uncontrollable growth, provoked by inappropriate signals that instruct the cells to keep dividing. Researchers at MIT and Brigham and Women’s Hospital have now identified ...
Jun 13, 2011 |
4.2 / 5 (6) |
2
|
Combination overcomes breast cancer resistance to herceptin
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson ...
Mar 13, 2011 |
4 / 5 (2) |
0
|
Researchers discover signaling pathway crucial to acute lung injury
Researchers at National Jewish Health have discovered a signaling pathway that is crucial to the devastating effects of acute lung injury (ALI). The data, obtained from cells, animals and ALI patients, suggest several potential ...
Medicine & Health / Medical research
Jan 31, 2011 |
not rated yet |
0
Tracking therapeutic nanoparticles that target breast tumors
Researchers at Rice University, collaborating with investigators at the Baylor College of Medicine, have used two different types of imaging technologies to track the delivery of a therapeutic nanoparticle to breast tumors. ...
Nanotechnology / Bio & Medicine
Dec 17, 2010 |
5 / 5 (2) |
0
|
I-SPY 2 study speeds up treatment for breast cancer
A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital.
Nov 19, 2010 |
5 / 5 (1) |
0
Fox Chase clinical trial tests first of its kind antibody
Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type ...
Jun 04, 2010 |
not rated yet |
0
Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
An international team of researchers has discovered molecular evidence that may explain why some women with HER2 over-expressing breast cancer do not respond to drugs designed to target this important molecule.
May 06, 2010 |
not rated yet |
0
New way discovered to predict which breast cancer patients should be treated with anthracyclines
An international team of researchers has discovered a new way of detecting which breast cancer patients are going to respond best to chemotherapy that includes anthracycline antibiotics.
Mar 25, 2010 |
not rated yet |
0
Antibody-guided drug shows encouraging activity in metastatic breast cancer
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from ...
Dec 12, 2009 |
5 / 5 (1) |
0
Targeted therapy prolongs life in patients with HER2-positive breast cancer
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine ...
Dec 11, 2009 |
5 / 5 (1) |
0
Combining nanotubes and antibodies for breast cancer 'search and destroy' missions
cylinders of carbon about a nanometer in diameter -- have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for ...
Dec 02, 2009 |
5 / 5 (1) |
0
Which is promising as therapeutic targets in patients with biliary tract cancer? EGFR or HER2?
A research team from Germany analyzed the pathogenetic role and potential clinical usefulness of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) in patients with advanced ...
Oct 16, 2009 |
not rated yet |
0
African American lung cancer patients may have different response to new cancer-fighting drugs
Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response ...
Oct 07, 2009 |
not rated yet |
0
Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin). Published in the November ...
Sep 14, 2009 |
not rated yet |
4
HER2/neu
HER2/neu (also known as ErbB-2) stands for "Human Epidermal growth factor Receptor 2" and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2/neu has also been designated as CD340 (cluster of differentiation 340) and p185. It is encoded by the ERBB2 gene.
For more information about HER2/neu, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
